Icatibant Hikma (Icatibant)

Icatibant is a selective antagonist of the bradykinin B2 receptor. It binds to this receptor and prevents bradykinin from triggering vasodilation and increased vascular permeability, which are the primary mechanisms that cause the swelling seen in hereditary angioedema attacks.

The prescribed dose of icatibant is determined by the treating physician based on the patient’s clinical condition and regulatory guidelines. Typically, a single subcutaneous injection is administered at the onset of an HAE attack, and the prescriber may repeat the dose if needed according to approved labeling.

Safety data for icatibant during pregnancy and lactation are limited. It should only be used when the potential benefit justifies any potential risk to the fetus or infant. Healthcare providers should discuss the lack of robust data with the patient and consider alternative therapies when appropriate.

To order Icatibant Hikma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and the necessary import documentation.

The primary alternative for HAE attacks is a plasma‑derived or recombinant C1‑esterase inhibitor (e.g., Berinert, Cinryze). While C1‑esterase inhibitors replace the deficient protein, icatibant directly blocks the bradykinin B2 receptor. Icatibant offers a rapid, subcutaneous route and does not require intravenous infusion, but both classes are effective and choice depends on patient preference, accessibility and clinical guidance.

Icatibant should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and do not freeze or shake the solution. If temporary storage at room temperature is unavoidable, limit exposure to no more than 30 days and return the product to refrigeration as soon as possible.

Icatibant is administered by subcutaneous injection, usually into the abdomen or thigh. The injection is performed by a healthcare professional or, after proper training, by the patient or caregiver. The injection site should be rotated for repeated administrations, and aseptic technique must be followed to minimize infection risk.

The most serious adverse events associated with icatibant include anaphylaxis, severe angioedema unrelated to HAE, and marked hypotension. Patients should be instructed to seek immediate medical attention if they experience difficulty breathing, swelling of the face or throat, rash, or a sudden drop in blood pressure after injection.

Icatibant is contraindicated in individuals with known hypersensitivity to icatibant or any of its excipients. It should also be used with caution in patients with severe cardiovascular disease, uncontrolled hypertension, or those taking medications that significantly affect blood pressure, until a risk‑benefit assessment is performed by a qualified clinician.